Phase II Study to Test Safety and Effectiveness of VC005 Gel for Adults with Mild to Moderate Atopic Dermatitis

What this Trial Is About

Researchers are evaluating the safety and effectiveness of a gel called VC005 in adults with mild to moderate atopic dermatitis. This phase II clinical trial is randomized, double-blind, and vehicle-controlled, meaning participants receive either the gel or a placebo without knowing which one. The study is conducted at multiple centers and sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Participants are assigned to one of four groups three different doses of VC005 gel or a placebo gel. All treatments involve local topical application directly to the affected skin areas. The study compares these groups in parallel to assess how the gel affects the severity and extent of eczema over a 4-week period. During the study, participants will be evaluated for changes in their eczema severity using the Eczema Area and Severity Index EASI at baseline and after 4 weeks. The researchers will monitor participants closely for any side effects or safety concerns. The study is designed for adults aged 18 years and older, and participants must meet specific diagnostic criteria for atopic dermatitis. The total study duration extends until February 2027.

A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis